FGFR3 and breast cancer: As shown in Fig. 1c–e, for all three BC cells, the synergistic inhibition is >0 for most of the concentration pairs we tested at low nanomolar concentrations, suggesting the synergy of erdafitinib and quisinostat in BC with FGFR3 fusions.